The HIV-1 associated dementia complex: A metabolic encephalopathy fueled by viral replication in mononuclear phagocytes

Current Opinion in Neurology

Volumn 10, Issue 4, 1997, Pages 319-325

  Zheng, Jialin ^a   Gendelman, Howard E ^a,b  

^a UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

^b UNIVERSITY OF NEBRASKA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN INFECTION; DEMENTIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; METABOLIC ENCEPHALOPATHY; NEUROPATHOLOGY; NEUROTOXICOLOGY; NONHUMAN; REVIEW; VIRUS REPLICATION;

EID: 0030860925     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199708000-00007     Document Type: Review

References (77)

1. Navia BA, Jordan BD, Price RW: The AIDS dementia complex: I. Clinical features. Annals of Neurology 1986, 19:517-524.
2. Gendelman HE, Persidsky Y, Ghorpade A, Limoges J, Stins M, Fiala M, Morrisett R: The neuropathic-genesis of AIDS dementia complex. AIDS 1997 11 (suppl A):S35-S45.
3. Gendelman HE: HIV-1 neuropathogenesis. In: The neurology of AIDS. Edited by Gendelman HE, Lipton SA, Epstein LG, Swindells S. New York: Chapman and Hall; 1997 (in press).
4. Bloom FE, Rausch DM: HIV in the brain: Pathology and neurobehavioral consequences. J NeuroVirology 1997, 3:102-109.
5. Persidsky Y, Gendelman HE: Development of laboratory and animal model systems for HIV-1 encephalitis and its associated dementia. J Leuk Biol 1997, 62 (in press).
6. Janssen RS, Nwanyanwu OC, Selik RM, Stehr-Green JK: Epidemiology of HIV encephalopathy in the United States. Neurology 1992, 42:1472-1476.
7. McArthur JC, Selves OA, Glass JD, Hoover DR, Bacellar H: HIV dementia: Incidence and risk factors. In: Price RW, Perry SW (eds): HIV, AIDS, and the Brain. New York: Raven Press, 1994:251-272.
8. Sanchez-Portocarrero J, Jimenez-Escrig, Perez-Cecilia E, Ayuso-Mateos JL, Roca V, Ruiz Yague M, Barquero M, Ramirez C, Varela de Seijas E: AIDS dementia complex: incidence, clinical profile and impact of Zidovudine treatment. European J Neurology 1996, 3:191-197.
9. Chiesi A, Vella S, Dally LG, Pedersen C, Danner S, Johnson AM, Schwander S, Goebel ED, Glauser M, Antunes F, Lundgren JD: Epidemiology of AIDS dementia complex in Europe. J AIDS Human Retrovirol 1996, 11:39-44.
10. Moore RD, Chaisson RE: Natural history of opportunistic disease in an HIV-infected urban clinical cohort. Ann Intern Med 1996, 124:633.
11. Budka H: Neuropathology of human immunodeficiency virus infection. Brain Pathol 1991, 1:63-175.
12. Kolson DL, Pomerantz RJ: AIDS dementia and HIV-1-induced neurotoxicity: possible pathogenic associations and mechanisms. J Biomed Sci 1996, 3:389-414.
13. Tyor WR, Glass JD, Griffin JW, Becker PS, McArthur JC, Bezman L, Griffin DE: Cytokine expression in the brain during AIDS. Ann Neurol 1992, 31:349-360.
14. Dollard SC, James HJ, Sharer LR, Epstein LG, Gelbard HA, Dewhurst S: Activation of nuclear factor kappa-β in brains from children with HIV-1 encephalitis. Neuropathol Appl Neurobiol 1995, 21:518-528.
15. Sippy BD, Hofman FM, Wallach D, Hinton DR: Increased expression of tumor necrosis factor-alpha receptors in the brains of patients with AIDS. AIDS Res Hum Retro 1995, 10:511-521.
16. Rho MB, Wesselingh S, Glass JD: A potential role for interferon-alpha in the pathogenesis of HIV-associated dementia. Brain Behav Immun 1995, 9:366-377.
17. Masliah E, Ge N, Achim CL, Wiley CA: Cytokine receptor alterations during HIV infection in the human central nervous system. Brain Res 1994, 663:1-6.
18. Weidenheim KM, Epshteyn T, Lyman WD: Immunocytochemical identification of T-cells in HIV-1 encephalitis: implication for pathogenesis of CNS disease. Mod Pathol 1993, 6:167-174.
19. Murray EA, Rausch DM, Lendvary J, Sharer LR, Eiden LE: Cognitive and motor impairment associated with SIV infection in rhesus monkeys. Science 1992, 255:1246-1249.
20. Stern Y, Liu X, Marder K, Todak G, Sano M, Ehrhardt A, German J: Neuropsychological changes in a prospectively followed cohort of gay and bisexual men with and without HIV infection. Neurology 1995, 45:467-472.
21. Sacktor N, Van Heertum RL, Dooneief G, German J, Khandji A, Marder K, Nour R, Todak G, Stern Y, Mayeux R: A comparison of cerebral SPECT abnormalities in HIV-positive homosexual men with and without cognitive impairment. Arch Neurol 1995, 52:1170-1173.
22. Marder K, Liu X, Stern Y, Malouf R, Dooneief G, Bell K, Todak G, Joseph M, Sorrell S, El Sadr W, Williams JBW, Ehrhardt A, Stein Z, Gorman J: Risk of HIV-1 related neurologic disease in a cohort of intravenous drug users. Arch Neurol 1995, 52:1174-1182.
23. Stern Y, Liu X, Marder K: Neuropsychological changes in a prospectively followed cohort of Intravenous drug users with and without HIV. Neuropsych Neuropsychol Beh Neurol 1996, 9:83-90.
24. Kibayashi K, Mastri AR, Hirsch CS: Neuropathology of human immunodeficiency virus infection at different disease stage. Hum Pathol 1996, 27:637-642.
25. Stern RA, Silva SG, Chaisson N, Evans DL: Influence of cognitive reserve on neuropsychological functioning in asymptotic human immunodefieiency virus-1 infection. Arch Neurol 1996, 53:148-153.
26. Janssen RS, Cornblath DR, Epstein LG: Nomenclature and research case definitions for neurological manifestations of human immunodeficincy virus type-1 (HIV-1) Infection: report of a Working Group of the American Academy of Neurology AIDS Task Force. Neurology 1991, 41:778-785.
27. The Dana Consortium on therapy for HIV dementia and related cognitive disorders: Clinical confirmation of the American Academy of Neurology algorithm for HIV-1 associated cognitive/motor disorder. Neurology 1996, 47:1247-125. A report by the Dana consortium on therapy for HIV dementia and related cognitive disorders confirmed the American Academy of Neurology's algorithm and found it rare to have both cognitive and functional impairments without associated neurologic and behavioral deficiencies. Dementia was found to be an independent predictor of physical outcome in affected patients.
28. McConnell JR, Swindells S, Ong CS, Gmeiner WH, Chu WK, Brown DK, Gendelman HE: Prospective utility of cerebral proton magnetic resonance spectroscopy in monitoring HIV infection and its associated neurological impairment. AIDS Res Hum Retro 1994, 10:977-982.
29. Tracey I, Carr CA, Guimaraes AR, Worth JL, Navia BA, Gonzalez RG: Brain choline containing compounds are elevated in HIV-positive patients before the onset of AIDS dementia complex. Neurology 1996, 46:783-788.
30. Kieburtz K, Ketonen L, Cox C, Grossman H, Holloway R, Booth H, Hickey C, Feigin A, Caine ED: Cognitive performance and regional brain volume in HIV-1 infection. Arch Neurol 1996, 53:155-158.
31. Koening S, Gendel HE, Orenstein JM, Canto MCD, Pezeshkpour GH, Yungbluth M, Janotta F, Aksamit A, Martin MA, Fauci AS: Detection of AIDS virus in macrophages in brain tissue from AIDS patients with encephalopathy. Science 1986, 233:1089-1093.
32. Wiley CA, Schrier RD, Nelson JA, Lampert PW, Oldstone MBA: Cellular localization of HIV infection within brains of AIDS syndrome patients. Proc Natl Acad Sci USA 1986; 83:7089-7093.
33. Weis S, Haug H, Budka H. Neuronal damage in the cerebral cortex of AIDS brains: a morphometric study. Acta Neuropathol 1993, 85:185-189.
34. Wiley CA, Masliah E, Morey M, Lemere C, Teresa R, Grate M, Hansen L, Terry R: Neocortical damage during HIV infection. Ann Neurol 1991, 29:651-657.
35. Yoshioka M, Shapshak P, Srivastava AK, Stewart RV, Nelson SJ, Bradley WG, Berger JR: Expression of HIV-1 and interleukin-6 in lumbosacral dorsal root gangalia of patients with AIDS. Neurology 1994, 44:1120-1130.
36. Nottet HSLM, Gendelman HE: Unraveling the neuroimmue mechanism for HIV-1 encephalitis. Immunol Today 1995, 16:441-448.
37. Masliah E, Ge N, Achim C, Wiley CA: Differential vulnerability of calbindin-immunoreactive neurons in HIV encephalitis. J Neurol Pathol Exp Neurol 1995, 54:350-357.
38. Takahashi K, Wesselingh SL, Griffin DE, McArthur JC, Johnson RT, Glass JD: Localization of HIV-1 in human brain using polymerase chain reaction/in situ hybridization and immunocytochemistry. Ann Neurol 1996, 39:705-711.
39. Glass JD, Fedor H, Wesselingh SL, McArthur JC: Immunocytochemical quantitation of human immunodeficiency virus in the brain: correlation with dementia. Ann Neurol 1995, 38:755-762.
40. Asare E, Dunn G, Glass J, McArthur J, Luthert P, Lantos P, Everall I: Neuronal pattern correlates with the severity of human immunodeficiency virus-associated dementia complex. Am J Pathol 1996, 148:31-38.
41. McGeer PL, McGeer EG: The inflammatory response system of brain: Implication for therapy of Alzheimer and other neurodegenerative diseases. Brain Res Review 1995, 21:195-218. The authors review recent progress in research involving the inflammatory responses of brain. The suggest that immune dysregulations in the CNS may be autotoxic for neurons, exacerbating the fundamental pathology in Alzheimer disease and perhaps other degenerative neurological disorders. New agents directed against the brain inflammatory processes showed in studies of Alzheimer disease may have broad therapeutic applications.
42. Brew BJ, Wesselingh SL, Gonzales M, Heyes MP, Price RW: How HIV leads to neurological disease. Med J Aust 1996, 164:233-234.
43. Gendelman HE, Lipton S, Tardien M, Bukrinsky MF, Nottet HSLM: The neuropathogenesis of HIV-1 infection. J Leuk Biol 1994, 56:389-399.
44. Lipton SA, Gendelman HE: Dementia associated with the acquired immunodeficiency syndrome. N Engl J Med 1995, 332:934-940.
45. Giulian D, Yu J, Xia L, Tom D, Li J, Lin SN, Schwarz R, Noonan, C: Study of receptor-mediated neurotoxins released by HIV-1 infected mononuclear phagocytes found in human brain. J Neurosci 1996, 16:3139-3153. In vitro reconstitution studies indicates that the macrophage product, NTox, produced following HIV-1 infection activate NMDA subtypes of glutamate receptor-operated synaptic ion channels at picomolar concentrations. This factor presumably results in necrotic neuronal injury/death.
46. Masliah E, Ge N, Achim CL, DeTeresa R, Wiley CA: Patterns of neurodegeneration in HIV encephalitis. NeuroAIDS 1996, 1:161-173.
47. Korber BTM, Kunstman KJ, Patterson BK, Furtabo M, McEvilly MM, Levy R, Wolinsky SM: Genetic differences between blood- and brain-derived viral sequence from HIV-1 infected patients: Evidence of conserved elements in the V3 region of the envelope protein of brain-derived sequences. J Virol 1994, 68:7467-7481.
48. Power C, McArthur JC, Johnson RT, Griffin DE, Glass JD, Perryman S, Chesebro B: Demented and non-demented patients with AIDS differ in brain-derived human HIV-1 envelope sequences. J Virol 1994, 68:4643-4649.
49. Di Stefano M, Wilt S, Gray F, Dubois-Dalcq M, Chiodi F: HIV-1 V3 sequences and the development of dementia during AIDS. AIDS Research and Human Retroviruses 1996, 12:471-476. HIV-1 variants found in brain or cerebrospinal fluid are genetically similar to those recovered from lymphoid tissue.
50. Reddy RT, Achim CL, Sirko DA, Tehranchi S, Kraus FG, Wong-Staal F, Wiley CA: Sequence analysis of the V3 loop in the brain and spleen of patients with HIV encephalitis. AIDS Research and Human Retroviruses 1996, 12:477-482. Brain-specific HIV-1 sequences were not observed suggesting that while CNS virus is macrophage tropic there remains no evidence that changes in the V3 region of the envelope glycoprotein of HIV-1 confer neurotropism.
51. Simmonds P: Neurotropism of HIV type 1? (Commentary). AIDS Research and Human Retroviruses 1996, 12:469-470.
52. Nottet HSLM, Jett M, Flanagan CR, Zhai QH, Persidsky Y, Rizzino A, Bernton EW, Genis P, Baldwin T, Schwartz J, LaBenz CJ, Gendelman HE: A regulatory role for astrocytes in HIV-1 encephalitis: an overexpression of eicosanoids, platelet-activating factor, and tumor necrosis factor-α by activated HIV-1-infected monocytes is attenuated by primary human astrocytes. J Immunol 1995, 154:3567-3581.
53. Adamson DC, Wildemann B, Sasaki M, Glass JD, McArthur JC, Christov VI, Dawson TM, Dawson VL: Immunologie NO synthase: elevation in severe AIDS dementia and Induction by HIV-1 gp41. Science 1996, 274:1917-1921. The levels of inducible nitric oxide synthase in severe ADC coincided with increased expression of the HIV-1 coat protein gp41 in affected brain tissue. Inducible nitric oxide synthase was induced by gp41 in primary cultures of mixed rat neuronal and glial cells. The data suggest that gp41-induced nitric oxide formation may contribute to the severe cognitive dysfunction associated with HIV-1 infection.
54. Gelbard HA, Dzenko K, Diloreto D, Del Cerro C, Del Cerro M, Epstein LG: Neurotoxic effects of tumor necrosis factor in primary human neuronal cultures are mediated by activation of the glutamate AMPA receptor subtypes implications for AIDS neuropathogenesis. Dev Neurosci 1993, 15:417-422.
55. Zheng J, Thylin M, Persidsky Y, Ghorpade A, Gendelman HE: The mechanism of neuronal dysfunction in HIV-1 associated dementia. Soc Neurosci Abs 1997, 23 (in press).
56. Deckwerth TL, Elliott JL, Knudson CM, Johnson EM, Snider WD, Korsmeyer SJ: BAX is required for neuronal death after trophic factor deprivation and during development. Neuron 1996, 17:401-411. The works demonstrates that neurotrophic factor deprivation-induced death of sympathetic and motor neurons is dependent on Bax.
57. Chao CC, Hu S, Sheng WS, Tsang M, Peterson PK: Tumor necrosis factor-α mediates the release of bioactive transforming growth factor β in microglial cell cultures. Clin Immunol Immunopathol 1995, 77:358-365. TNF-α (a candidate HIV-1-induced neurotoxin) is produced from immune compentent microglia and can elicit the production of biologically active forms of TGF-β.
58. Prehn JH, Peruche B, Unsicker K, Kreiglstein J: Isofrom-specific effects of transforming growth factor-β on degeneration of primary neuronal cultures induced by cytotoxic hypoxia or glutamate. J Neurochem 1993, 60:1665-1672.
59. Chao CC, Hu S, Kravitz FH, Tsang M, Anderson WH, Peterson PK: Transforming growth factor-β protects human neurons against β-amyloid-induced injury. Molec Chem Neuropathol 1994, 23:159-178.
60. Meucci O, Miller RJ: Gp120-induced neurotoxiclty in hippocampal pyramidal neuron cultures: protective action of TGF-β1. J Neurosci 1996, 16:4080-1086. TGF-β1, a cytokine that has been reported to have an important neuroprotective role, was able to prevent the neurotoxicity induced by the HIV-1 coat protein gp120 in hippocampal pyramidal neurons.
61. Johnson MD, Gold LI: Distribution of transforming growth factor-β isoform in human immunodeficiency virus-1 encephalitis. Hum Pathol 1996, 27:643-649.
62. Bonfoco E, Kraing D, Ankarcrona M, Nicotera P, Lipton SA: Apoptosis and necrosis: two distinct events induced, respectively, by mild and intense insults with N-methyl-D-aspartate or nitric oxide/superoxide in cortical cell cultures. Proc Natl Acad Sci USA 1995, 92:7162-7166.
63. New DR, Ma M, Epstein LG, Nath A, Gelbard HA: Human immunodeficiency virus type 1 tat protein induces death by apoptosis in primary human neuron cultures. J Neurovirol 1997, 3:168-173. HIV-1 tat protein induces neuronal cell death by an apoptotic process in primary human neuronal cultures.
64. Gelbard HA, James H, Sharer L, Perry SW, Saito Y, Kazee AM, Blumberg BM, Epstein LG: Identification of apoptotic neurons in post-mortem brain tissue with HIV-1 encephalitis and progressive encephalopathy. Neuropathol Appl Neurobiol 1995, 21:208-217.
65. Petito CK, Roberts B: Evidence of apoptotic cell death in HIV encephalitis. Am J Pathol 1995, 146:1121-1130.
66. An SF, Giometto B, Scaravilli T, Tavolato B, Gray F, Scaravilli F: Programmed cell death in brains of HIV-1-positive AIDS and pre-AIDS patients. Acta Neuropathol 1996, 91:169-173.
67. Adle-Biassette H, Levy Y, Colombel M, Poron F, Natchev S, Keohane C, Gray F: Neuronal apoptosis in HIV infection in adults. Neuropathol Appl Neurobiol 1995, 21:218-227.
68. Gelbard HA, Nottet HSLM, Swindells S, Jett M, Dzenko KA, Genis P, White R, Wang L, Choi YB, Zhang D: Platelet-activating factor: a candidate human immunodeficiency virus type 1-induced neurotoxin. J Virol 1994, 68:4628-4635.
69. Nottet HSLM, Persidsky Y, Sasseville VG, Nukuna AN, Bock P, Zhai QH, Sharer LR, McComb R, Swindells S, Soderland C, Rizzino A, Gendelman HE: Mechanisms for the transendothelial migration of HIV-1-infected monocytes into brain. J Immunol 1996, 156:1284-1295. HIV entry into brain is, in part, a consequence of the ability of virus-infected and immune-activated monocytes to induce adhesion molecules, such as E-selectin and vascular cell adhesion molecule-1 (VCAM-1) on brain microvascular endothelium.
70. Sasseville VG, Smith MM, Mackay CR, Pauley DR, Mansfield KG, Ringler DJ, Lackner AA: Chemokine expression in simian immunodeficiency virus-induced AIDS encephalitis. Am J Pathol 1996, 149:1459-1467. Encephalitic brains from SIV-infected animals have increased levels of the C-C chemokines, macrophage inflammatory protein-1α and -β, RANTES monocyte chemoactic protein-3, and the C-X-C chemokine interferon-inducible protein-10. These findings suggest that one or all of these chemokines could be involved in monocyte recruitment into the CNS.
71. Persidsky Y, Stins M, Way D, Witte MH, Weinand M, Kim KS, Bock P, Gendelman HE, Fiala M: A model for monocyte migration through the blood-brain barrier during HIV-1 encephalitis. J Immunol 1997, 158:3499-3510. An artifical BBB model was constructed that allows an analysis of HIV-1 and monocyte penetration into the brain. The transendothelial migration of monocytes through this BBB system demonstrates that immune activation, not viral infection, is the major event that permits immune cell entry into brain tissue.
72. Persidsky Y, Nottet HSLM, Sasseville VG, Epstein LG, Gendelman HE: The development of animal model systems for HIV-1 encephalitis and associated dementia. J Neurovirol 1995, 1:229-243.
73. Toggas SM, Masliah E, Rockenstein EM, Rall GF, Abraham CR, Mucke L: Central nervous system damage produced by expression of the HIV-1 coat protein gp-120 in transgenic mice. Nature 1994, 367:188-193.
74. Persidsky Y, Limoges J, McComb R, Bock P, Baldwin T, Tyor W, Patil A, Nottet HSLM, Epstein L, Gelbard H, Flanagan E, Reinhard J, Pirruccello SJ, Gendelman HE: Human immunodeficiency virus encephalitis in SCID mice. Am J Pathol 1996, 149:1027-1053. This model of HIV-1 encephalitis utilizes SCID mice lacking functional B and T-cells due to a defect in T-cell receptor and immunoglobulin variable chain rearrangement. This allows the animals to accept human monocytes without rejection. The model demonstrates that human monocytes can synthesize neurotoxins that cross species (human to mouse) and can reproduce key aspects of HIV encephalitis in the animals.
75. Bell JE, Donaldson YK, Lowrie S, McKenzie CA, Elton RA, Chiswick A, Brettle RP, Ironside JW, Simmonds P: Influence of risk group and Zidovudine therapy on the development of HIV encephalitis and cognitive impairment in AIDS patients. AIDS 1996, 10:493-499.
76. Chretien F, Gray F, Truchis P, Belec L, Levy Y, Dubreuil-Lemaire ML: Protection of human Immunodeficiency virus encephalitis by a switch from Zidovudine to Didanosine. Antimicrobial Agents and Chemotherapy 1996, 40:278.
77. Sacktor N, McArthur J: Prospects for therapy of HIV-associated neurologic diseases. J Neurovirol 1997, 3:89-101.